Trial Profile

Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 17 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VOY 101 (Primary)
Indications Age-related macular degeneration
Focus Adverse reactions
Sponsors Perceive Biotherapeutics

Most Recent Events

10 Apr 2024 Status changed from recruiting to active, no longer recruiting.
17 Nov 2022 Status changed from not yet recruiting to recruiting.
17 Nov 2022 Planned End Date changed from 1 Oct 2025 to 1 Nov 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com